Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05106491

Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients

The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Krankenhaus Buchholz und Winsen gGmbH, Buchholz, Germany

Loading trial locations.

About this study

The current study hypothesizes that The SCS treatment with the icor kit provides sufficient support for cardiocirculatory function as indicated by a significant lactate reduction 24 hours on SCS treatment versus before treatment start.

Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support.

Synchronized Cardiac Support describes an electrocardiogram (ECG)- triggered pulsatile VA-ECMO based on R-wave detection. During diastole the pump speed and thus the flow is increased and during systole the pump flow is been set on a relative minimum. This provides a mechanical circulatory support pulse with oxygenated blood during diastole.

The Synchronized Cardiac Support Treatment is used in a standard VA ECMO configuration by two femoral single vessel cannulas. Patients following cardiac resuscitation will undergo targeted temperature management 32- 36°C according to guideline.

The Duration of Treatment can be up to 14 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent signed and dated by study patient/legal representative and investigator/authorised physician
  • Minimum age of 18 years
  • Patients in cardiogenic shock
  • Cardiogenic shock is defined as:
  • Systolic blood pressure < 90 mmHg for at least 30 min
  • Inotropes and/or vasopressors are needed to maintain systolic blood pressure > 90 mmHg
  • Clinical signs of heart insufficiency with pulmonary congestion
  • Signs of end organ hypoperfusion with at least one of the following criteria:
  • Cold, damp skin or extremities
  • Oliguria (≤ 30 mL/h)
  • Serum lactate > 3.0 mmol/L

Exclusion criteria

  • In case of female patients: pregnancy or lactation period
  • Participation in an interventional clinical study during the preceding 30 days
  • Previous participation in the same study
  • Age > 85 years
  • Cardiac arrest out of hospital with return of spontaneous circulation (ROSC) > 30 min
  • No flow time > 5 min
  • Mechanical causes for cardiogenic shock (ventricular septal defect of papillary muscle rupture)
  • Non-cardiogenic causes of shock (bradycardia, sepsis, hypovolemia, etc.)
  • Fever (Body temperature > 38.0 °C) or other evidence of sepsis
  • Onset of cardiogenic shock > 6 h before enrolment
  • Lactate > 16 mmol/L
  • Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters
  • Contra-indications for anticoagulation
  • Contra-indication for VA ECMO, e.g. unrecoverable heart and not a candidate for transplant or VAD

Treatment and study plan

Synchronized Cardiac Support with the icor kit

Device

Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).

Other names: Synchronized Cardiac Support (icor)

Primary outcomes

  1. Cardiocirculatory stabilization and end-organ perfusion

    Time frame: up to 14 days

    measured by the Change in Lactate Level

Secondary outcomes

  1. Cardiocirculatory stabilization and end-organ perfusion

    Time frame: up to 14 days

    measured by the following parameter: Mean Arterial Pressure, Catecholamine Support, Cardiac Index, Cardiac Output and Cardiac Afterload

  2. Maintain gas exchange

    Time frame: up to 14 days

    measured by the following parameter: Blood Gas Analysis and Mechanical Ventilation

  3. Extracorporeal Life Support (ECLS) Performance

    Time frame: up to 14 days

    measured by the following parameter: Blood Flow, Blood Pressure, Synchronization of the patient's heartbeat, Intra-hospital transportation

  4. Maintain renal function

    Time frame: up to 14 days

    measured by the following parameter: Fluid Balance, Renal Replacement Therapy, Creatinine and eGRF

  5. Thermoregulation

    Time frame: up to 14 days

    measured by the the Body Temperature

Other outcomes

  1. Safety Variables

    Time frame: up to 14 days

    • Severe adverse events, i.e. Hemolysis Bleeding
    • Severe adverse device events

Study contacts

Contact information is provided by the study sponsor or research team.

Anja Derlet-Savoia, Dr.

CONTACT

[email protected]

+49 6172 2686648

Celina Erfle

CONTACT

[email protected]

+49 6172 2686809

Sponsors and collaborators

Lead sponsor

Xenios AG

Industry

Registry information

Official study title

Evaluating the Efficacy and Safety of the Synchronized Cardiac Support Treatment with the Icor Kit in Patients with Cardiogenic Shock - a Pivotal Study (Pulse SE)

Acronym: PulseSE

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 3, 2021
Registry last updated
Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.